针对胃肠道癌症的个性化新辅助化疗:塑造不精确的精确
Dan Høgdall1,2, Jakob V Schou1, Julia Johanna Almer Bromann1
1Department of Oncology, Herlev and Gentofte Hospital, Herlev, Copenhagen University Hospital, Copenhagen, Denmark.
概括
使用瘤生物学来个性化消化肠道癌症的新辅助化疗可以改善治疗结果. 量身定制的策略可以减少副作用并增加治疗性手术的发生率,特别是在耐药瘤中.
科学领域:
- 在瘤学瘤学.
- 胃肠道癌症研究研究
- 精准医学是一门精准的医学.
背景情况:
- 新辅助化疗提供了潜在的好处,如减少瘤和减少胃肠道癌症复发.
- 目前的治疗方案往往是普遍的,缺乏个性化,并导致许多患者的最佳结果.
- 瘤异质性和对标准治疗方案的不同反应突显出需要更精确的治疗方法.
研究的目的:
- 强调利用瘤生物学在个性化新辅助化疗中开发预测特征的关键作用.
- 探索个性化治疗策略如何改善外科手术候选性并减少胃肠道恶性瘤的治疗强度.
- 倡导精确方法的整合,以提高新辅助化疗的疗效和患者的治疗结果.
主要方法:
- 利用转录学来分析患者活检,并了解治疗反应的分子基础.
- 根据已识别的瘤脆弱性和临床前数据,识别现有和新型治疗剂.
- 比较分子上不同的患者群体接受量身定制化疗方案与标准化疗方案的结果.
主要成果:
- 有证据表明,在大多数胃肠道瘤中存在可操作的敏感性和可向的依赖性,支持个性化治疗.
- 个性化新辅助化疗有望增加治疗耐药癌症的治愈性手术率,如胆道和胰腺管腺癌.
- 量身定制的化疗可以在更敏感的癌症中降低剂量和降低发病率,而不会影响瘤学结果.
结论:
- 以瘤生物学为指导的个性化新辅助化疗对于优化胃肠道癌症治疗至关重要.
- 开发预测特征对于将患者与最有效的化疗方案或新药匹配至关重要.
- 实施精确方法可以显著改善新辅助治疗结果,降低毒性,并增加治疗性手术的潜力.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493